Dr. Reddy's Laboratories rises Tuesday, still underperforms market
Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...
Dr Reddy's clocks highest-ever revenue in Q2; net profit down 9.5%
Hyderabad-based Dr Reddy's Laboratories (DRL) posted a 9.5 per cent year-on-year (Y-o-Y) decline in its consolidated ...
Daily11h
Dr Reddy's Labs recalls over 3 lakh bottles of Cinacalcet tablets in US over manufacturing issues
Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets, a medication used for treatment of high ...
Benzinga.com8h
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17%
Dr. Reddy's Q2 net income dropped to $160 million from $177M YoY, with revenue up 16.6% to $957 million. Global generics revenue grew 17% YoY, driven by sales volume gains and new launches. Dr.
Dr Reddy's R&D expenses to stay around 8.5% in FY25, to launch key biosimilar in 2027
Much like the trend in the domestic pharma industry, Dr Reddy's Laboratories is investing heavily in research and development aimed at ramping up the biosimilars, generics, and biologics segments.
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...
Dr. Reddy’s to expand GLP-1 portfolio with focus on obesity and diabetes drug markets
With Novo Nordisk’s patent on semaglutide set to expire in India, Dr Reddy’s is among the forerunners trying to bring the ...
Dr Reddys Share Price Today Live Updates: Dr. Reddy's experiences minor price increase
Stay up-to-date with the Dr Reddys Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...